Bioteque (4107) reported revenue of NT$200.9 million for Oct 2026, +2.4% year on year and +2.7% from the previous month. Revenue for Jan–Oct 2026 was NT$1.92 billion (+8.6% year on year).
Revenue for Oct 2026 was a record high (previous high: May 2026, NT$197.3 million). →
Year-on-year revenue growth: 8 months in a row. →
In Oct 2026, it ranked No. 40 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$200.9 million | +2.4% | +2.7% |
| Sep 2026 | NT$195.5 million | +10.4% | +1.4% |
| Aug 2026 | NT$192.8 million | +17.4% | +0.0% |
| Jul 2026 | NT$192.9 million | +8.4% | -2.2% |
| Jun 2026 | NT$197.2 million | +12.2% | +0.0% |
| May 2026 | NT$197.3 million | +14.3% | +1.9% |
| Apr 2026 | NT$193.7 million | +6.4% | -0.3% |
| Mar 2026 | NT$194.2 million | +11.7% | +20.1% |
| Feb 2026 | NT$161.6 million | -12.7% | -15.2% |
| Jan 2026 | NT$190.7 million | +19.5% | +0.5% |
| Dec 2025 | NT$189.6 million | +19.7% | +4.5% |
| Nov 2025 | NT$181.4 million | +2.7% | -7.5% |
| Oct 2025 | NT$196.1 million | +15.9% | +10.7% |
| Sep 2025 | NT$177.1 million | +1.7% | +7.8% |
| Aug 2025 | NT$164.3 million | -10.6% | -7.6% |
| Jul 2025 | NT$177.9 million | -8.9% | +1.2% |
| Jun 2025 | NT$175.7 million | +0.5% | +1.7% |
| May 2025 | NT$172.7 million | -0.8% | -5.1% |
| Apr 2025 | NT$182 million | +7.2% | +4.7% |
| Mar 2025 | NT$173.9 million | +2.3% | -6.1% |
| Feb 2025 | NT$185.1 million | +24.9% | +16.0% |
| Jan 2025 | NT$159.6 million | -10.4% | +0.7% |
| Dec 2024 | NT$158.5 million | -10.2% | -10.2% |
| Nov 2024 | NT$176.6 million | +3.7% | +4.4% |
| Oct 2024 | NT$169.2 million | -1.5% | -2.9% |
Jan–Oct 2026 cumulative: NT$1.92 billion (+8.6% YoY)
Other Biotech & Medical companies
Compare with peers: Bioteque vs PEC / Bioteque vs Lotus Pharm / Bioteque vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16